MHLW (Japan) approves Jcovden (formerly Ad26.COV2.-S) vaccine for COVID-19.- Janssen Pharmaceuticals KK
Japan health ministry (MHLW) approved Janssen Pharmaceutical’s COVID-19 vaccine Jcovden.
Jcovden (formerly Ad26.COV2.-S), a recombinant vector vaccine, has now become the fifth vaccine approved in Japan against the novel coronavirus, but it is the only one among the five that requires just a single shot for primary inoculations.
It is approved for those aged 18 and older, but the government does not plan to incorporate it into the publicly funded emergency vaccination program. The vaccine was filed in May 2021, and although it was subject to priority review, it took more than one year to land approval due to delays in the company’s submission of additional documents requested by the regulators.
Related news and insights
The FDA has approved crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over 1 year of age.
Bayer announced the FDA has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Myovant Sciences and Pfizer Inc. announced that the FDA)has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.